A Galapagos company

CellPoint

Redefining the future of cancer treatment with a decentralized, innovative point-of-care CAR-T manufacturing platform

Pioneering for patients
with Galapagos

CellPoint was a biotechnology company founded in 2018 in the Netherlands. They developed a decentralized point-of-care CAR-T manufacturing model. In 2022 CellPoint was acquired by Galapagos. Since then, they have been united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. Thus, we will be sharing all company updates, news, and insights on Galapagos’ website.

If you are looking for the acquisition details, we invite you to have a look at our factsheet.

A decentralized, innovative point-of-care CAR-T manufacturing platform

Galapagos’ decentralized, innovative point-of-care CAR-T manufacturing platform consists of a proprietary end-to-end xCellit™ workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control (QC) testing and release strategy.

The combination of these three core components allows for the administration of a fresh product, a median vein-to-vein time of 7 days (i.e. the time between T-cell collection and CAR-T infusion), and greater physicians oversight throughout the process.

Redefining the Future of Cancer Treatment

Discover Galapagos’ decentralized, innovative point-of-care CAR-T manufacturing platform. It consists of a proprietary end-to-end xCellit™ workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control (QC) testing and release strategy.

Latest news

Stay in the know about our progress, and visit our Newsroom

Our stories

Read more about how we are #LivingInnovation in our stories

Investor hub

Looking for information about our company, our stock and our financials?